| Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline consists of two compounds: seclidemstat (SP-2577), a small molecular inhibitor and SP-3164, a small molecular protein degrader. SP-2577 is a small-molecule lysine specific demethylase 1 (LSD1) inhibitor with a scaffold. LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth. SP-3164 is a cereblon binding molecular glue. SP-3164 degrades transcription factors IKZF1 and IKZF3, along with other proteins, resulting in both direct anti-cancer activity and immune-modulating properties. SP-3164 has activity in both hematologic and solid tumors. We show 18 historical shares outstanding datapoints in our SLRX shares outstanding history coverage, used to compute SLRX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SLRX market cap history over the course of time is important for investors
interested in comparing SLRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SLRX versus a peer is one thing; comparing
SLRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SLRX can fluctuate over the course of history.
With this page we aim to empower investors researching SLRX by allowing them to research the SLRX market cap history.